Global Breast Cancer Market 2014-2018

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Treatment Regimen for Breast Cancer
08. Market Segmentation by Type of Therapy
09. Market Segmentation by Molecule Type
10. Global Monoclonal Antibodies Market in Breast Cancer
11. Clinical Pipeline Portfolio
12. Geographical Segmentation
12.1 Breast Cancer Drugs Market in the Americas
12.1.1 Market Size and Forecast
12.2 Breast Cancer Drugs Market in the EMEA Region
12.2.1 Market Size and Forecast
12.3 Breast Cancer Drugs Market in the APAC Region
12.3.1 Market Size and Forecast
12.3.2 Country-wise Segmentation of APAC  2013
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.2.1 F. Hoffmann-La Roche Ltd.
20.2.2 Astrazeneca PLC
20.2.3 Novartis AG
20.2.4 Sanofi-Aventis
20.2.5 Eli Lilly and Company
20.3 Other Prominent Vendors
20.4 Future Players Expected to Tap the Market
21. Key Vendor Analysis